Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Effectiveness and Efficiency of Home Telemonitoring and Non-invasive Ventilation in Patients With COPD and Hypercapnia (EVALECO) (EVALECO)

29. Juni 2026 aktualisiert von: Air Liquide Healthcare Spain

Effectiveness and Efficiency of Home Telemonitoring and Non-invasive Ventilation in Patients With COPD and Hypercapnia

The purpose of this study is to evaluate the effectiveness and clinical efficiency of combining home non-invasive ventilation (NIV) with a continuous remote telemonitoring (TM) system in patients with Chronic Obstructive Pulmonary Disease (COPD) and persistent hypercapnia. In standard practice, patients with severe COPD and high carbon dioxide levels in their blood are treated with home non-invasive ventilation to support their breathing. This study compares two different care strategies over a one-year follow-up period:

  1. One group of patients will receive standard home non-invasive ventilation alone.
  2. Another group will receive home non-invasive ventilation combined with an automated telemonitoring system that tracks device parameters daily (such as air leaks, device usage, and breathing rates) and sends automated alerts to the healthcare team if deviations occur. The main goal of the project is to determine if adding a telemonitoring follow-up system can prevent clinical worsenings and significantly reduce the total number of days patients spend hospitalized due to severe COPD flare-ups. Additionally, the study will analyze the impact of both strategies on patients' overall health-related quality of life and the economic costs within the healthcare system.

Studienübersicht

Detaillierte Beschreibung

Background and Rationale:

Chronic Obstructive Pulmonary Disease (COPD) with persistent hypercapnia is associated with increased mortality, functional decline, and high healthcare costs. While home non-invasive ventilation (NIV) is established as standard care to correct chronic respiratory failure, integrating remote telemonitoring (TM) presents an opportunity to implement early clinical interventions by allowing continuous oversight of ventilator parameters.

Study Design and Setting:

This is a prospective, multicenter, comparative cohort study with an integrated economic and utility evaluation. The study will be conducted across 5 public university hospitals within the Community of Madrid, Spain. A total of 92 patients (46 patients in the NIV+TM cohort and 46 in the conventional NIV cohort).

Study Hypotheses:

  • Conceptual Hypothesis: Patients managed with the combined NIV+TM strategy experience a better clinical course than those treated with standard NIV alone.
  • Statistical Hypothesis: Patients in the NIV+TM group will experience a lower average burden of exacerbation-related hospitalizations (estimated average of 24 days over 12 months) compared to the conventional NIV group (estimated average of 32 days over 12 months), reflecting a significant reduction of 8 hospital days between both management strategies during the first year of treatment.

Description of Cohorts and Follow-up Interventions:

  • Combined Ventilation and Telemonitoring Cohort (NIV+TM): Patients receive standard advanced pressure-controlled nocturnal NIV combined with a remote data transmission modem. Clinical parameters-including device compliance, residual Apnea-Hypopnea Index (AHI), intentional/unintentional air leaks, respiratory rate (RR), and tidal volume (Vt)-are continuously monitored. Automated alerts are prioritized by the system: Low Priority alerts are tracked during routine visits, while High Priority alerts trigger an explicit, standardized clinical decision algorithm. This algorithm mandates immediate telephone triage, home technician visits for equipment adjustments, or direct communication with the prescribing pulmonologist for parameter adjustments. Domiciliary visits and health-related quality of life assessments (EQ-5D-5L and Severe Respiratory Insufficiency [SRI] questionnaires) will be carried out at baseline, 30, 90, 180, 270, and 365 days.
  • Conventional Ventilation Cohort (NIV alone):

Patients receive identical advanced pressure-controlled nocturnal NIV settings but without remote data monitoring capabilities. Follow-up follows conventional guidelines based on standard clinical dependence: monthly home visits for patients requiring >12 hours/day of ventilation, or quarterly home visits for those requiring ≤12 hours/day. Compliance data, air leaks, and adaptation are checked manually during these visits. In-person follow-ups, EQ-5D-5L, and SRI assessments occur at baseline, day 30, and regular domiciliary visits, alongside mandatory arterial blood gas monitoring at 3, 6, and 12 months to verify treatment efficacy.

Economic and Data Analysis:

Analytical evaluations will be performed on an intention-to-treat basis. Clinical outcomes, utility values (Quality-Adjusted Life Years - QALYs gained calculated via Spanish EQ-5D-5L utility weights), and direct medical/non-medical healthcare system costs (utilizing the most recent official public tariffs from the Madrid Health Service - SERMAS) will be combined. Incremental Cost-Effectiveness Ratios (ICER), Incremental Cost-Utility Ratios (ICUR), and Incremental Cost-Benefit ratios will be constructed to evaluate healthcare efficiency. Uncertainty will be addressed via a deterministic sensitivity analysis assessing baseline, best-case, and worst-case scenarios for the telemonitoring implementation.

We have updated the Study Description to remove the term 'randomly allocated' to avoid misunderstanding. This is a strictly observational study where participants receive interventions (NIV or NIV+TM) as part of routine medical care based on institutional availability and clinical criteria, not by investigator assignment. To minimize selection bias inherent to the observational nature of the study, a consecutive sampling methodology and a post-hoc matching or adjusted statistical analysis using a block-restrictive system based on clinical variables was utilized, ensuring the investigator does not prospectively assign interventions.

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

92

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Probenahmeverfahren

Wahrscheinlichkeitsstichprobe

Studienpopulation

The study population consists of adult patients diagnosed with severe, stable Chronic Obstructive Pulmonary Disease (COPD) and chronic persistent hypercapnia, who are managed and followed at public university hospitals within the Community of Madrid, Spain, and who have a recent history of frequent acute respiratory exacerbations.

Beschreibung

Inclusion Criteria:

  1. Age between 50 and 90 years.
  2. Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) according to current Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria, demonstrating non-fully reversible airflow limitation with a Forced Expiratory Volume in 1 second (FEV1) < 50% of the predicted value confirmed by spirometry.
  3. Persistent hypercapnia, defined as PaCO2 > 53 mmHg documented for at least two weeks following an acute COPD exacerbation.
  4. History of two or more acute COPD exacerbations within the preceding year.
  5. Signed written informed consent.

Exclusion Criteria:

  1. Prior ongoing treatment with home non-invasive ventilation (NIV) or Continuous Positive Airway Pressure (CPAP).
  2. Severe obstructive sleep apnea (OSA), defined as an Apnea-Hypopnea Index (AHI) >= 30.
  3. Inability of the patient or the primary caregiver to comprehend or operate the telemonitoring and NIV procedures.
  4. Estimated life expectancy of less than one year.
  5. Terminal heart failure (New York Heart Association [NYHA] Class III-IV) or unstable angina.
  6. Advanced renal insufficiency (creatinine clearance < 30%) or inclusion in an active dialysis program.
  7. Hepatic cirrhosis or active inclusion in a liver transplant program.
  8. Severe psychiatric illness requiring antipsychotic medication, active ongoing treatment for substance or alcohol addiction, or lack of a fixed home address upon hospital discharge.
  9. Receipt of home palliative care.
  10. Institutionalization.
  11. Classification by the attending physician as non-compliant with medical therapies, treatments, or study protocols

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

Kohorten und Interventionen

Gruppe / Kohorte
Intervention / Behandlung
NIV+TM Cohort
Patients managed with a combined strategy consisting of advanced pressure-controlled nocturnal home non-invasive ventilation (NIV) and continuous remote telemonitoring (TM). Device compliance, residual Apnea-Hypopnea Index (AHI), air leaks, respiratory rate, and tidal volume are monitored daily. High-priority automated alerts trigger a standardized clinical decision algorithm, requiring immediate telephone triage or parameter modifications.
Use of nocturnal home non-invasive ventilation devices equipped with or without integrated digital modems for automated parameter monitoring (compliance, leaks, residual AHI, respiratory rate, and tidal volume) over a 12-month follow-up period.
Conventional NIV Cohort
Patients managed with conventional home non-invasive ventilation (NIV) following standard follow-up guidelines based on clinical dependence, without remote telemonitoring or automatic alert systems. Compliance and leak data are verified manually during scheduled domiciliary visits (monthly or quarterly depending on daily ventilation hours).

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Number of prevented days of hospitalization due to COPD acute exacerbations
Zeitfenster: 12 months
The total number of days a patient spends hospitalized in a general hospital ward or Intensive Care Unit (ICU) due to acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD). An acute exacerbation is defined according to GOLD criteria as an increase in dyspnea, cough, and/or sputum worsening in less than 14 days.
12 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Health-Related Quality of Life and Utility (QALYs)
Zeitfenster: Baseline, 30 days, 90 days, 180 days, 270 days, and 365 days.
Measured using the validated Spanish version of the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire. It evaluates 2 continuous components: the Visual Analogue Scale (VAS, scored 0-100) and the EQ-Index (scored 0-1, where 1 represents perfect health and 0 represents death). These scores will be utilized to calculate Quality-Adjusted Life Years (QALYs) gained.
Baseline, 30 days, 90 days, 180 days, 270 days, and 365 days.
Number of Acute COPD Exacerbations
Zeitfenster: 12 months
Total count of localized respiratory worsening events matching the GOLD definition (worsening of dyspnea, cough, or sputum) experienced by patients during the study.
12 months
Number of Hospital Admissions due to COPD Exacerbations
Zeitfenster: 12 months
Total number of formal hospital admissions required due to severe acute respiratory deteriorations.
12 months
Number of Emergency Department Visit
Zeitfenster: 12 months
Total count of unexpected visits to hospital emergency rooms or primary care emergency facilities necessitated by acute COPD flare-ups.
12 months
Time to first acute COPD exacerbation
Zeitfenster: Up to 12 months
The specific time period (measured in days) elapsed from the baseline treatment initiation until the documentation of the patient's first acute COPD exacerbation event.
Up to 12 months
Direct Healthcare Costs
Zeitfenster: 12 months
Total direct medical and non-medical healthcare resources consumed per patient (including non-invasive ventilation service costs, telemonitoring setup, emergency visits, and hospitalization days in regular wards or ICU), calculated by applying official public healthcare tariffs from the Madrid Health Service (SERMAS).
12 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. Juli 2026

Primärer Abschluss (Geschätzt)

1. Juli 2026

Studienabschluss (Geschätzt)

1. Dezember 2026

Studienanmeldedaten

Zuerst eingereicht

23. Juni 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

29. Juni 2026

Zuerst gepostet (Tatsächlich)

1. Juli 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

1. Juli 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

29. Juni 2026

Zuletzt verifiziert

1. Juni 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

Individual participant data will not be shared externally due to strict patient confidentiality, data privacy, and legal regulations. In compliance with Spanish Organic Law 3/2018 (GDPR implementation) and the Patient Autonomy Law 41/2002, the link between patient identity and their study code is exclusively known and held by their attending physician[cite: 660, 685, 690, 691]. All clinical data collected are managed within a closed, pseudonymized centralized electronic platform (ReseaArch®) under a strict role-based access control architecture. External distribution of raw individual datasets is neither covered by the patient informed consent nor approved by the participating institutional ethics committees.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

3
Abonnieren